Leerink Partnrs Decreases Earnings Estimates for ICON Public

ICON Public Limited (NASDAQ:ICLR) – Analysts at Leerink Partnrs dropped their FY2025 earnings estimates for shares of ICON Public in a report issued on Tuesday, November 19th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings per share of $14.11 for the year, down from their previous forecast of $14.58. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.42 per share. Leerink Partnrs also issued estimates for ICON Public’s FY2026 earnings at $15.94 EPS and FY2027 earnings at $17.95 EPS.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the prior year, the firm earned $3.10 earnings per share. The company’s revenue was down 1.2% on a year-over-year basis.

Other equities analysts also recently issued reports about the stock. Barclays reduced their price objective on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. TD Cowen decreased their price objective on ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a report on Friday, October 25th. StockNews.com lowered ICON Public from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. JPMorgan Chase & Co. cut their target price on ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Finally, Redburn Atlantic initiated coverage on ICON Public in a research report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price target on the stock. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, ICON Public presently has an average rating of “Moderate Buy” and a consensus target price of $292.45.

ICON Public Stock Up 4.5 %

Shares of ICLR stock opened at $212.76 on Thursday. ICON Public has a one year low of $183.38 and a one year high of $347.72. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The stock has a fifty day moving average price of $259.64 and a 200 day moving average price of $298.45. The stock has a market cap of $17.55 billion, a P/E ratio of 23.72, a price-to-earnings-growth ratio of 1.45 and a beta of 1.25.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Kornitzer Capital Management Inc. KS boosted its stake in shares of ICON Public by 15.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock valued at $30,016,000 after purchasing an additional 13,163 shares during the last quarter. GAMMA Investing LLC grew its holdings in ICON Public by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after acquiring an additional 87 shares during the period. Sara Bay Financial bought a new stake in shares of ICON Public during the 3rd quarter valued at $1,143,000. Whittier Trust Co. lifted its stake in shares of ICON Public by 8.6% in the 2nd quarter. Whittier Trust Co. now owns 3,579 shares of the medical research company’s stock valued at $1,122,000 after purchasing an additional 284 shares during the period. Finally, Arkadios Wealth Advisors boosted its position in shares of ICON Public by 67.7% in the 2nd quarter. Arkadios Wealth Advisors now owns 1,231 shares of the medical research company’s stock worth $386,000 after purchasing an additional 497 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.